Panel Sequencing for Targeted Therapy Selection in Solid Tumors - 21/09/22
, Lynette Sholl, MD b, Dara Aisner, MD, PhD aRésumé |
The genetic testing of solid tumors has evolved rapidly. With an ever-increasing number of clinically significant and/or actionable gene alterations in addition to increasing biologic, gene, or mutation-specific therapies, single-target testing is no longer suitable for many modern oncology patients. This review explores panel-based testing, including its history and evolution from prior testing modalities. We also discuss its current usefulness, as best exemplified by lung cancer, and other special considerations including a summary of the pros and cons of panel implementation and use. Lastly, we discuss the successes and challenges of panel-based testing and explore future directions.
Le texte complet de cet article est disponible en PDF.Keywords : Next-generation sequencing (NGS), Panel, Solid tumor, Targeted, Sequencing, Therapy
Plan
Vol 42 - N° 3
P. 309-323 - septembre 2022 Retour au numéro
Article précédent
- The Medical Practice of Molecular Oncology Diagnostics
- Fei Dong
- Molecular Diagnostic Testing for Hematopoietic Neoplasms : Linking Pathogenic Drivers to Personalized Diagnosis
- Christopher B. Hergott, Annette S. Kim
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?